Mixed connective tissue disease: An overview of clinical manifestations, diagnosis and treatment

被引:84
作者
Ortega-Hernandez, Oscar-Danilo [1 ]
Shoenfeld, Yehuda [1 ,2 ]
机构
[1] Chaim Sheba Med Ctr, Zabludowicz Ctr Autoimmune Dis, IL-52621 Tel Hashomer, Israel
[2] Laura Schwarz Kip Chair Res Autoimmune Dis, Tel Aviv, Israel
来源
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY | 2012年 / 26卷 / 01期
关键词
Mixed connective tissue disease; Raynaud's phenomenon; Erosive arthritis; Anti-RNP antibodies; Myositis; Organ involvement and treatment; SYSTEMIC-LUPUS-ERYTHEMATOSUS; PULMONARY ARTERIAL-HYPERTENSION; ANTI-RNP ANTIBODIES; RAYNAUDS-PHENOMENON; OVERLAP SYNDROME; ANTIPHOSPHOLIPID ANTIBODIES; SEROLOGIC CHARACTERISTICS; ESOPHAGEAL INVOLVEMENT; ANTI-U1RNP ANTIBODIES; TRIGEMINAL NEURALGIA;
D O I
10.1016/j.berh.2012.01.009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The most common clinical manifestations of mixed connective disease are Raynaud's phenomenon, arthralgias, swollen joints, esophageal dysfunction, muscle weakness and fingers sausage-like appearance together with the presence of anti-ribonucleoprotein (RNP) antibodies. However, organ involvement is more extensive than first descriptions reported. The disease can be serious with development of pulmonary, kidney, cardiovascular, gastrointestinal and central nervous system manifestations. The worst prognosis and high mortality are associated with the presence of pulmonary disease. Although a different set of clinical criteria have been proposed, there is no consensus about the most accurate. There is no full agreement about treatment and the initial impression of a satisfactory response to low doses of steroids is not always the rule. Herein, we review available evidence to a better approach to all previous topics. Crown Copyright (C) 2012 Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:61 / 72
页数:12
相关论文
共 100 条
[1]  
ALARCONSEGOVIA D, 1989, J RHEUMATOL, V16, P328
[2]   CARDIOVASCULAR MANIFESTATIONS OF MIXED CONNECTIVE-TISSUE DISEASE IN ADULTS [J].
ALPERT, MA ;
GOLDBERG, SH ;
SINGSEN, BH ;
DURHAM, JB ;
SHARP, GC ;
AHMAD, M ;
MADIGAN, NP ;
HURST, DP ;
SULLIVAN, WD .
CIRCULATION, 1983, 68 (06) :1182-1193
[3]  
Amigues JM, 1996, J RHEUMATOL, V23, P2055
[4]  
Anon Alarcon-Segovia D., 1987, Mixed connective tissue disease and antinuclear antibodies, P33
[5]   The prevalence and clinical significance of anti-U1 RNA antibodies in patients with systemic sclerosis [J].
Asano, Y ;
Ihn, H ;
Yamane, K ;
Kubo, M ;
Tamaki, K .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2003, 120 (02) :204-210
[6]  
BABINI SM, 1985, J RHEUMATOL, V12, P160
[7]  
BARAKAT S, 1991, CLIN EXP IMMUNOL, V86, P71
[8]   Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus [J].
Barile-Fabris, L ;
Ariza-Andraca, R ;
Olguín-Ortega, L ;
Jara, LJ ;
Fraga-Mouret, A ;
Miranda-Limón, JM ;
de la Mata, JF ;
Clark, P ;
Vargas, F ;
Alcocer-Varela, J .
ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (04) :620-625
[9]   PLEURITIS-PERICARDITIS - AN UNUSUAL INITIAL MANIFESTATION OF MIXED CONNECTIVE-TISSUE DISEASE [J].
BEIER, JM ;
NIELSEN, HL ;
NIELSEN, D .
EUROPEAN HEART JOURNAL, 1992, 13 (06) :859-861
[10]   ARTHRITIS OF MIXED CONNECTIVE-TISSUE DISEASE [J].
BENNETT, RM ;
OCONNELL, DJ .
ANNALS OF THE RHEUMATIC DISEASES, 1978, 37 (05) :397-403